Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
CMPI was delisted on the 27th of May, 2022.
36 hedge funds and large institutions have $236M invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 4 closing their positions.
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
27% more capital invested
Capital invested by funds: $186M → $236M (+$49.7M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
3% less funds holding
Funds holding: 37 → 36 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$838K |
| 2 |
State Street
Boston,
Massachusetts
|
+$250K |
| 3 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$243K |
| 4 |
Bank of New York Mellon
New York
|
+$222K |
| 5 |
JP Morgan Chase
New York
|
+$143K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$661K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$624K |
| 3 |
Millennium Management
New York
|
-$616K |
| 4 |
CCM
CAAS Capital Management
New York
|
-$518K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$294K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $55K | +$38.2K | +3,000 | +400% |
|
27
UBS Group
Zurich,
Switzerland
| $43K | +$29.3K | +2,302 | +355% |
|
28
Wells Fargo
San Francisco,
California
| $39K | +$16.6K | +1,303 | +93% |
|
|
SO
29
STRS Ohio
Columbus,
Ohio
| $29K | +$8.92K | +700 | +54% |
|
|
TRCT
30
Tower Research Capital (TRC)
New York
| $19K | -$69.9K | -5,486 | -81% |
|
31
Citigroup
New York
| $15K | +$9.9K | +777 | +321% |
|
32
Bank of Montreal
Toronto,
Ontario, Canada
| $12K | +$7.18K | +564 | +240% |
|
33
Legal & General Group
London,
United Kingdom
| $8K | – | – | – |
|
|
AIP
34
Ameritas Investment Partners
Lincoln,
Nebraska
| $6K | – | – | – |
|
35
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | +$4.28K | +336 | New |
|
|
AIG
36
American International Group
New York
| $43 | -$1.07K | -84 | -3% |
|
|
CCM
37
CAAS Capital Management
New York
| – | -$518K | -44,966 | Closed |
|
|
ZP
38
Zimmer Partners
New York
| – | -$288K | -25,000 | Closed |
|
39
Goldman Sachs
New York
| – | -$145K | -12,600 | Closed |
|
|
MCM
40
Moore Capital Management
New York
| – | -$115K | -10,000 | Closed |
|
CMPI Hedge Fund Activity: Q4 2020 in Review
36 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q4 2020, worth a combined $236M — up 27% from $186M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of CMPI and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 13 added.
The largest buyer was Vanguard Group, adding an estimated $838K. The largest seller was Sectoral Asset Management, cutting an estimated $661K.
- 36 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q4 2020, down from 37 in Q3 2020.
- Funds reported $236M of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q4 2020, up 27% quarter-over-quarter.
- 3 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 4 closed out, a net change of -1 holder.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Vanguard Group, an estimated $838K added.
- The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Sectoral Asset Management, an estimated $661K sold.
Based on aggregated 13F filings for Q4 2020.